Pythiosis is a rapidly progressing disease that can be lethal to affected individuals due to resistance to available therapeutic protocols. The disease affects mammals, with the largest number of reports in horses and humans. The present study investigated the activity of biogenic silver nanoparticles (bioAgNP) in the treatment of experimental pythiosis. The disease was reproduced in nine female 90-day-old New Zealand rabbits. Animals were divided into three groups: group1 (control, n = 3) daily and topically treated with a nonionized gel-based formulation and 1 ml of sterile distilled water intralesion administered every 48 hours; group 2 (n = 3), daily and topically treated with gel-based formulation containing 1 μg/ml bio-AgNP; group 3 (n = 3), treated with 1 ml bio-AgNP in 1 μg/ml aqueous solution intralesion administered every 48 hours. Animals were treated for 45 days, and the area of subcutaneous lesions was measured every 5 days. Results showed that groups 2 and 3 differed from control group (P < .05) in the lesion area, as well as the amount of hyphae within the lesions. It was observed that lesions of treated animals (groups 2 and 3) did not differ from each other, showing that the application route did not influence the regression of lesions. However, it was observed that one animal from group 2 reached clinical cure at 35 days of treatment. This research is pioneer in the application of nanocomposites for the treatment of experimental pythiosis and showed that bio-AgNP can be powerful allies of integrative medicine and can be included in pythiosis therapeutic protocols.

中文翻译：

---

生物银纳米颗粒在化脓性脓毒症实验中的治疗Bio-AgNP。

硫烟病是一种快速发展的疾病，由于对可用治疗方案的耐药性，可能对受影响的个体致死。该病影响哺乳动物，在马和人类中报道最多。本研究调查了生物银纳米颗粒（bioAgNP）在治疗实验性硫烟病中的活性。该疾病在九只90天大的新西兰大白兔中繁殖。将动物分为三组： 每天第1组（对照组，n＝ 3），并以基于非离子凝胶的制剂局部治疗，每48小时给予1ml无菌蒸馏水损伤；第2组（n  = 3），每天并用含有1μg/ ml bio-AgNP的凝胶制剂局部治疗；组3（Ñ = 3），每48小时用1 ml bio-AgNP在1μg/ ml水溶液中的病灶内治疗。治疗动物45天，每5天测量一次皮下病变区域。结果显示，第2组和第3组与对照组（P <.05）以及病变区域内的菌丝数量。观察到治疗动物（第2组和第3组）的病变没有彼此不同，这表明施用途径不影响病变的消退。但是，观察到，第2组的一只动物在治疗35天时就达到了临床治愈。这项研究是纳米复合材料在治疗实验性脓毒症中的应用的先驱，并表明生物-AgNP可以成为强大的综合医学同盟者，并可以包含在脓毒症治疗方案中。